

PRN PharmaFarm recently published findings from an internal database of ophthalmic pharmaceutical and device companies with a new product in development.¹

We identified 190 companies developing ophthalmic products. Of these, 134 were privately held and 56 publicly held.



In the United States there were 136 companies: 50 located in the West, 45 in the Northeast, 29 in the South and 11 in the Midwest and 1 in the Virgin Islands. The states that had the most companies were: California (n=43), Massachusetts (n=19), and New York (n=9).

There were 54 companies located outside the United States of which the most were in: Switzerland (n=7), France (n=7), Israel (n=6) and the United Kingdom (n=6).



28% companies outside the USA



72% companies in the USA

Of the 190 companies identified there were 436 total products with 338 being pharmaceuticals and 98 treatment devices.





78% pharmaceuticals

22% devices





The pharmaceuticals included 46 separate indications of which the most common, just over 50% of all products (n=173), were: wet and dry age-related macular degeneration (AMD, n=75), glaucoma (n=52) and dry eye (n=46).

Devices included 30 separate indications with the most common being glaucoma (n=26) and AMD (n=19).



AMD, glaucoma and dry eye were by far the most popular treatment indications for pharmaceutical development



For the pharmaceuticals the most common broad product classes were: anti-inflammatory (n=35), hormone therapy (n=33), anti-vascular endothelial growth factor (n=25), monoclonal antibody (n=21) and gene therapy (n=27).

Anti-inflammatory and hormone were the most popular pharmaceutical product classes



The most common product classes with the medical devices were ocular implants (n=25) and drug delivery (n=19).



Ocular implants and drug delivery were the most popular device product classes

This study suggests ophthalmology as a specialty is benefited by a wide effort in new medicine and device development.

However, a concentration of effort into relatively few indications in pharmaceutical products hints to a potential lack of market analysis and possible difficulty for many companies in commercializing their product.

For a copy of this infographic for your own use please [click here](#).

1. Sharpe RA, Austin JP, Kruff B, Nelson LA, Stewart JA, Stewart WC. Description of ophthalmic pharmaceutical and device start-up companies. *Ophthalmic Res* 2015; in press.